Abstract: A method for judging deformation of a vertebral body includes the steps of measuring a central length (a), rear brim length (c), and front brim length (d) from a profile X-ray image of a vertebral body to be judged, determining ratios of c/d, a/c and a/d, and classifying deformation of the vertebral body to be judged by using indices, c, d, c/d, a/c and a/d. Furthermore, a method for judging deformation of a vertebral body, which comprises obtaining at least two indices by measuring a central length (a), vertebral body width (b), rear brim length (c), and front brim length (d) from a profile X-ray image of a vertebral body, analyzing these indices by a discriminant function, and classifying a deformation of the vertebral body from results of the analysis.

Abstract: A method for evaluating cancellous bone from a density pattern of the cancellous bone obtained by irradiating the cancellous bone with a radiation wherein trabeculae of the cancellous bone are analyzed based on a power spectrum obtained by a Fourier transformation of the density pattern is provided.Furthermore, a method for evaluating cancellous bone from the density pattern of the cancellous bone obtained by irradiating the cancellous bone with radiation, wherein the density pattern is determined by irradiating the radiation substantially vertically against the main trabecula of the cancellous bone and the degree of the bone atrophy of the cancellous bone is evaluated by using the area (.SIGMA.GS) of the density pattern and/or the value (.SIGMA.GS/D) obtained by dividing the area (.SIGMA.GS) by the bone width (D) of the cancellous bone.

Abstract: The present invention relates to a method for treating an injured part on the oral mucosa, which comprises covering the injured part with a covering material consisting essentially of a cellulose lower alkyl ether and a polyacrylic acid or its pharmaceutically acceptable salt, and to said covering material.According to the present invention, without using a medicament, the injured part on an oral mucosa can be cured rather rapidly simply by covering the injured part.

Abstract: A pharmaceutical composition for intrarectal administration comprising a pharmaceutically effective amount of an active ingredient which when administered alone to the rectum, is substantially unabsorbable into the living body through the mucous membrane of the rectum, said composition further containing an absorption aid acting within the rectum in such a way as to induce absorption of said active ingredient through the rectal mucous membrane, said absorption aid being characterized by (1) being substantially nontoxic to living organisms, (2) containing in the molecule at least two hydrophilic groups selected from the class consisting of carboxyl groups, acidic hydroxyl groups, carboxyl groups in the form of pharmaceutically acceptable salts, acidic hydroxyl groups in the form of pharmaceutically acceptable salts, carboxyl groups in the form of amides and acidic hydroxyl groups in the form of esters, (3) containing in the molecule at least two lipophilic groups selected from the class consisting of groups of

Abstract: The present invention provides an albumin-fixed resin comprising a crosslinked water-insoluble resin and albumin chemically bound thereto, said water-insoluble resin being a crosslinked epoxy resin containing about 1 to about 30 milliequivalents of amino groups and about 1 to about 50 milliequivalents of hydroxyl groups per gram thereof, said albumin being ionically bound to the amino groups of the epoxy resin and to the hydroxyl groups by hydrogen bonding, and the amount of said albumin fixed being at least about 25% by weight based on the epoxy resin, and also provides a process for producing the albumin-fixed resin, which comprises(1) (a) subjecting a polyepoxy compound containing at least two epoxy groups in the molecule and a polyamine compound containing at least two primary and/or secondary amino groups in the molecule to addition reaction in an inert medium to produce a fully crosslinked resin, or (b) subjecting said compounds to addition reaction to produce an insufficiently crosslinked pre-polymer,

Abstract: A powdery pharmaceutical composition and a powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37.degree. C. for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug; and a method for treating or preventing a human nasal disease, which comprises administering a powdery preparation in unit dosage form to the nasal cavity of a human being requiring treatment or prevention of a nasal disease through his nostrils.

Abstract: PCT No. PCT/JP79/00284 Sec. 371 Date Nov. 6, 1979 Sec. 102(e) Date July 7, 1980 PCT Filed July 7, 1980 PCT Pub. No. WO80/00916 PCT Pub. Date May 15, 1980A medical preparation composed of an adhesive layer comprising polymers which have adhesiveness to a wet mucous surface and swellability upon moistening and a nonadhesive layer which has no adhesiveness to a wet mucous surface and is water soluble or water disintegrable, with at least one of the layers made to contain a medicament. The medical preparation is administered by adhering to a wet mucous surface of the mucous membrane and skin of men or animals, whereby exhibiting a property to release the medicament slowly extending over a long period of time to cure or prevent general or local diseases.

Abstract: In a method of obtaining purified 2,6-naphthalenedicarboxylic acid dimethyl ester by vacuum distilling crude 2,6-naphthalenedicarboxylic acid dimethyl ester under conditions of application of heat, the improvement which comprises vacuum distilling a crude 2,6-naphthalenedicarboxylic acid dimethyl ester having an acid value (A.sub.f), as expressed in milligrams of KOH required for neutralizing the carboxyl groups contained in one gram of said crude 2,6-naphthalenedicarboxylic acid dimethyl ester, of from 1.0 to 50.

Abstract: A process for preparing dimethyl 2,6-naphthalenedicarboxylate, which comprises continuously esterifying 2,6-naphthalenedicarboxylic acid with methanol at a temperature of about 140.degree. to about 350.degree. C. in the presence or absence of an esterifying catalyst, said 2,6-naphthalenedicarboxylic acid being fed into an esterification reaction zone in the form of solid particles having a specific surface area of about 4,000 cm.sup.2 /g.

Abstract: A novel 1,3,5,7-naphthalenetetracarboxylic acid, an alkali salt thereof, or an ester thereof, and a novel process for preparation thereof, and method of effective purification thereof.